Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail

Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects.